Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer

NCT ID: NCT04135313

Last Updated: 2021-02-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 540 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-10-20
• Study Completion Date: 2024-10-31

Brief Summary

The purpose of this study is to determine whether the addition of 2 cycles of induction CapOx chemotherapy and 2 cycles of consolidation CapOx chemotherapy to standard chemoradiation improves 3-year disease-free survival in patients with locally advanced CRM"+" mid and low rectal cancer.

Detailed Description

This trial aims to investigate the efficacy of adding neoadjuvant induction and consolidation chemotherapy compared to standard chemoradiotherapy in locally advanced rectal cancer patients with circumferential resection margin involvement. This is a prospective multicenter open-label randomized phase III clinical trial. Patients will be randomized using an online randomization system to receive either 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy OR chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), surgery (10-12 weeks following chemoradiotherapy) and 6 cycles of adjuvant CapOx chemotherapy. A stratification will be performed based on N stage, tumor location in the middle or low rectum and clinical center. Patients with middle or low rectal cancer without distant metastases, with involved circumferential resection margin (based on pretreatment MRI) will be included.

The target accrual is 270 patients in each treatment arm (including 10% potential data loss) based on potential benefit of 12% 3-yr disease-free survival (60% vs 72%), α=0,05, power 80% in the experimental arm. An interim analysis is planned after 50% of the patients will reach a 3-year followup. Pelvic Magnetic Resonance Imaging (MRI) is performed in all patients for staging before and after neoadjuvant chemotherapy and before surgery. Pelvic MRI is subject to central review. Conduction of this study and data collection are controlled by a local institutional board.

Conditions

Rectal Neoplasms Malignant; Rectum Carcinoma; Rectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Neoadjuvant chemotherapy

Patients receive 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy

Group Type: EXPERIMENTAL

Capecitabine

Intervention Type: DRUG

2000 mg/m2, bid, per os, days 1-14

Oxaliplatin

Intervention Type: DRUG

130 mg/m2 iv day 1

Capecitabine

Intervention Type: DRUG

825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)

Radiotherapy

Intervention Type: RADIATION

Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions

Rectal cancer surgery

Intervention Type: PROCEDURE

Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection

Chemoradiotherpy

Patients receive 54 Gy pelvic chemoradiotherapy in 2 Gy fractions with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 10-12 weeks. After surgery patients receive 6 cycles of adjuvant CapOx chemotherapy.

Group Type: ACTIVE_COMPARATOR

Capecitabine

Intervention Type: DRUG

2000 mg/m2, bid, per os, days 1-14

Oxaliplatin

Intervention Type: DRUG

130 mg/m2 iv day 1

Capecitabine

Intervention Type: DRUG

825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)

Radiotherapy

Intervention Type: RADIATION

Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions

Rectal cancer surgery

Intervention Type: PROCEDURE

Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection

Interventions

Capecitabine

2000 mg/m2, bid, per os, days 1-14

Intervention Type: DRUG

Oxaliplatin

130 mg/m2 iv day 1

Intervention Type: DRUG

Capecitabine

825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)

Intervention Type: DRUG

Radiotherapy

Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions

Intervention Type: RADIATION

Rectal cancer surgery

Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection

Intervention Type: PROCEDURE

Other Intervention Names

Xeloda; Xeloda

Eligibility Criteria

Inclusion Criteria

• Informed consent
• Histologically verified colon rectal adenocarcinoma 0-10 cm above the anal verge
• No distant metastases
• Circumferential resection margin (CRM) involvement (based on pelvic MRI)
• Eastern Cooperative Oncology Group (ECOG) status 0-2
• Haemoglobin (HGB) > 90 g/L
• Platelet Count (PLT) > 120x10*9/L
• Serum creatinine < 150 µmol/L
• Total bilirubin < 25 µmol/L

Exclusion Criteria

• inability to obtain informed consent
• distant metastases
• cT2N0M0 rectal cancer
• synchronous or metachronous tumors
• previous chemotherapy or radiotherapy
• clinically significant cardiovascular disorders (myocardial infarction < 6 months before visit, stroke < < 6 months before visit, instable angina < 3 months before visit, arrhythmia, uncontrolled hypertension > 160/100 mm hg
• clinically significant neurological disorders
• previous neuropathy 2 or higher
• current infection or heavy systemic disease
• pregnancy, breastfeeding
• ulcerative colitis
• individual intolerance to treatment components
• proven dihydropyrimidine dehydrogenase (DPD) deficiency
• participation in other clinical trials
• psychiatric disorders, which render patient unable to follow instructions or understand his/her condition
• technical inability to perform pelvic MRI
• inability of long-term followup of the patient
• HIV

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Blokhin's Russian Cancer Research Center

OTHER

Sponsor Role: lead

Responsible Party

Sergey Gordeyev

Principal Investigator, Consultant surgeon

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Zaman Z Mamedli, PhD

Role: PRINCIPAL_INVESTIGATOR

N.N.Blokhin Russian Cancer Research Center

Locations

N.N.Blokhin Russian Cancer Research Center

Moscow, , Russia

Countries

Russia

Other Identifiers

RuCorT-03

Identifier Type: -

Identifier Source: org_study_id